EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TLR8 Stimulation Leads to Microenvironment Activation and Enhanced Antibody-Dependent Cellular Responses in CLL

Giovanna Merchand-Reyes, Gauri Anyarambhatla, Maria L Valencia Pena, Renie Mensah-Bonsu, Ramasamy Santhanam, Xiaokui Mo, Frank H Robledo-Avila iD, Susheela Tridandapani, Jonathan P Butchar

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27188003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Giovanna Merchand-Reyes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA. Hauptthemen laut MEDLINE: Toll-Like Receptor 8, Leukemia, Lymphocytic, Chronic, B-Cell, Tumor Microenvironment, Antibody-Dependent Cell Cytotoxicity. Die Arbeit nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, The Ohio State University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toll-like receptors (TLRs) are crucial for eliciting immune responses against pathogens such as bacteria and viruses. TLR activation has also been studied for its potential to drive antitumor activity in immune cells. TLR8 is an intracellular receptor that recognizes single-stranded RNA and promotes antiviral responses, including the release of cytokines such as TNFα and type I IFN. Previously we have shown that TLR8 activation can also modulate the expression of Fcγ receptors (FcγR), which are major drivers of antibody-mediated tumor cell clearance. Hence, TLR8 agonist treatment represents a potential means of overcoming tumor-related immunosuppression and enhancing the efficacy of antibody therapy. In chronic lymphocytic leukemia, the use of therapeutic antibodies against CD20 has become standard for treatment. However, the immune effector cells show suppressed phenotypes and weakened responses compared to their healthy-donor counterparts. Here, we investigated TLR8 agonist treatment as a means to overcome this immune suppression and enhance cellular antibody-mediated responses. Upon stimulation with the agonist TL8-506, primary CLL-patient monocytes showed an increase in the expression of activating FcγR in conjunction with reduced expression of regulatory receptors. Cytokine production was also enhanced and there was a shift in phenotypic markers, suggesting the adoption of a more M1-like state. Treatment with TLR8 agonist also elicited production of IFNγ and Granzyme B and enhanced antibody-dependent cellular cytotoxicity of antibody-coated B cells by NK cells. Agonist treatment also increased the phagocytic activity of neutrophils but did not affect the formation of neutrophil extracellular traps (NETs). Taken together, these results suggest that TLR8 agonists may help counteract the suppressed phenotypes of immune effector cells and may enhance the efficacy of antibody therapy for CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 8Leukemia, Lymphocytic, Chronic, B-CellTumor MicroenvironmentAntibody-Dependent Cell CytotoxicityHumansToll-Like Receptor AgonistsReceptors, IgGCytokinesMonocytesKiller Cells, Natural

Stichwörter der Autor:innen

Fc receptorsNK cellsToll-like receptorsinnate immunitymonocytesneutrophils

Substanzen

Toll-Like Receptor 8TLR8 protein, humanToll-Like Receptor AgonistsReceptors, IgGCytokines

Autor:innen und Institutionen

  • Department of Internal Medicine, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
  • Department of Radiation Oncology, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
  • Center for Biostatistics, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
  • Department of Biomedical Informatics, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
  • Center for Microbe and Immunity Research, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH 43205, USA.

ORCID-Profile: Frank H Robledo-Avila

Förderung

  • NCI NIH HHS
  • NIH HHS
  • The Ohio State University
  • NIH NCI
  • OSU Division of Hematology Sponsored Research Program

Zitieren

APA

Merchand-Reyes, G., Anyarambhatla, G., Valencia Pena, M. L., Mensah-Bonsu, R., Santhanam, R., Mo, X., Robledo-Avila, F. H., Tridandapani, S., & Butchar, J. P. (2026). TLR8 Stimulation Leads to Microenvironment Activation and Enhanced Antibody-Dependent Cellular Responses in CLL. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188003

Vancouver

Merchand-Reyes G, Anyarambhatla G, Valencia Pena ML, Mensah-Bonsu R, Santhanam R, Mo X, et al. TLR8 Stimulation Leads to Microenvironment Activation and Enhanced Antibody-Dependent Cellular Responses in CLL. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188003

BibTeX
@article{MerchandReyes2026,
  author = {Merchand-Reyes, Giovanna and Anyarambhatla, Gauri and Valencia Pena, Maria L and Mensah-Bonsu, Renie and Santhanam, Ramasamy and Mo, Xiaokui and Robledo-Avila, Frank H and Tridandapani, Susheela and Butchar, Jonathan P},
  title = {TLR8 Stimulation Leads to Microenvironment Activation and Enhanced Antibody-Dependent Cellular Responses in CLL},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27188003}
}
Kostenlos starten →